Plain-English translation of NCT07053072 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new vaccine called PD-1 mRNA LNP vaccine for people with advanced liver cancer that has failed standard therapy. The vaccine works by teaching your immune system to recognize and fight cancer cells. Researchers want to find out if this medication is safe and whether it can help control or shrink tumors.
Advanced liver cancer that stops responding to standard treatments has very few options left. This medication takes a different approach by activating your own immune system rather than using traditional chemotherapy, offering hope for patients who have exhausted other treatments.
You likely qualify if…
You likely don't qualify if…
You would receive injections of the medication at different dose levels (the trial tests a lower dose first, then a higher dose) and visit the hospital regularly for check-ups, blood tests, and imaging scans to see how the treatment is working and to monitor for any side effects. The trial is very small — only about 9 people total will be enrolled — and your doctors will carefully watch your response to determine the safest and most effective dose.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
West China Hospital
Enrollment target
~9 participants
Started
October 2025
Primary completion
September 2026
Age range
18 Years – 70 Years
Last updated on clinicaltrials.gov in April 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Xingchen Peng
West China Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.